Literature DB >> 15323385

Outcome of equids with clinical signs of West Nile virus infection and factors associated with death.

Patricia Salazar1, Josie L Traub-Dargatz, Paul S Morley, Delwin D Wilmot, David J Steffen, Wayne E Cunningham, M D Salman.   

Abstract

OBJECTIVE: To determine outcome of equids in the western United States with clinical signs of West Nile virus (WNV) infection and identify factors associated with risk of death in infected equids.
DESIGN: Cross-sectional study. ANIMALS: 484 equids in Nebraska and Colorado. PROCEDURE: Owners of 484 equids with laboratory-confirmed West Nile virus infection in Nebraska and Colorado were contacted by telephone, and a questionnaire was used to obtain information on signalment, management, clinical signs, date of disease onset, duration of disease, WNV vaccination status, and health status at the time of the interview.
RESULTS: 137 of 482 (28.4%) animals died or were euthanatized. Ataxia, lethargy, muscle fasciculations, and weakness were the most common clinical signs of disease. Animals > or = 3 years old were more likely to die than were animals < or = 2 years old. Unvaccinated equids were twice as likely to die as were animals that had been vaccinated at least once prior to the onset of disease. Animals that were recumbent and unable to rise were 78 times as likely to die as were animals that never lost the ability to rise. Females were 2.9 times as likely to die as males. Two hundred seventy-one of 339 (79.9%) animals that survived recovered fully; mean duration of disease for these animals was 22.3 days. CONCLUSIONS AND CLINICAL RELEVANCE: Among equids with WNV infection, age, vaccination status, an inability to rise, and sex were associated with the risk of death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15323385     DOI: 10.2460/javma.2004.225.267

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  18 in total

Review 1.  West Nile virus: A re-emerging pathogen revisited.

Authors:  Miguel A Martín-Acebes; Juan-Carlos Saiz
Journal:  World J Virol       Date:  2012-04-12

2.  Surveillance of West Nile virus in horses in Canada: A retrospective study of cases reported to the Canadian Food Inspection Agency from 2003 to 2019.

Authors:  Antoine Levasseur; Julie Arsenault; Julie Paré
Journal:  Can Vet J       Date:  2021-05       Impact factor: 1.008

3.  Factors associated with the risk of West Nile virus among crows in New York State.

Authors:  C H DeCarlo; A B Clark; K J McGowan; P E Ziegler; A L Glaser; B Szonyi; H O Mohammed
Journal:  Zoonoses Public Health       Date:  2010-08-12       Impact factor: 2.702

4.  A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.

Authors:  Julie E Ledgerwood; Theodore C Pierson; Sarah A Hubka; Niraj Desai; Steve Rucker; Ingelise J Gordon; Mary E Enama; Steevenson Nelson; Martha Nason; Wenjuan Gu; Nikkida Bundrant; Richard A Koup; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2011-03-11       Impact factor: 5.226

5.  West Nile Virus equine serosurvey in the Czech and Slovak republics.

Authors:  Zdenek Hubálek; Eva Ludvíková; Petr Jahn; František Treml; Ivo Rudolf; Petra Svobodová; Silvie Šikutová; Lenka Betášová; Jozef Bíreš; Miroslav Mojžíš; Martin Tinák; Martin Boldižár; Gabriela Citsoňová; Zuzana Staššíková
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-06       Impact factor: 2.133

6.  A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.

Authors:  Julie E Martin; Theodore C Pierson; Sarah Hubka; Steve Rucker; Ingelise J Gordon; Mary E Enama; Charla A Andrews; Qing Xu; Brent S Davis; Martha Nason; Michael Fay; Richard A Koup; Mario Roederer; Robert T Bailer; Phillip L Gomez; John R Mascola; Gwong-Jen J Chang; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

7.  Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.

Authors:  K K Seino; M T Long; E P J Gibbs; R A Bowen; S E Beachboard; P P Humphrey; M A Dixon; M A Bourgeois
Journal:  Clin Vaccine Immunol       Date:  2007-08-08

Review 8.  West Nile viral infection of equids.

Authors:  J Angenvoort; A C Brault; R A Bowen; M H Groschup
Journal:  Vet Microbiol       Date:  2013-08-28       Impact factor: 3.293

9.  The economic impact of West Nile virus infection in horses in the North Dakota equine industry in 2002.

Authors:  M Ndiva Mongoh; R Hearne; N W Dyer; M L Khaitsa
Journal:  Trop Anim Health Prod       Date:  2008-01       Impact factor: 1.559

10.  Factors associated with West Nile virus disease fatalities in horses.

Authors:  Tasha Epp; Cheryl Waldner; Keith West; Hugh Townsend
Journal:  Can Vet J       Date:  2007-11       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.